Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive drug therapy

W J McCune1

  • 1University of Michigan Medical Center, Division of Rheumatology, Taubman Center, Ann Arbor 48109-0358, USA.

Current Opinion in Rheumatology
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda.

Lupus·2018
Same author

The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Lupus·2018
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Increased usage of special educational services by children born to mothers with systemic lupus erythematosus and antiphospholipid antibodies.

Lupus science & medicine·2014
Same author

In utero azathioprine exposure and increased utilization of special educational services in children born to mothers with systemic lupus erythematosus.

Arthritis care & research·2012
Same author

Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2012
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Cyclophosphamide shows promise for lupus nephritis but lacks proven efficacy in severe vasculitis. Its use in neurologic conditions, including lupus and multiple sclerosis, requires further investigation due to unclear mechanisms and objective outcome measures.

Area of Science:

  • Immunology
  • Neurology
  • Rheumatology

Background:

  • Intravenous cyclophosphamide is used for autoimmune diseases.
  • Efficacy is established in lupus nephritis but not severe vasculitis or Wegener's granulomatosis.
  • Neurologic manifestations present unique treatment challenges.

Purpose of the Study:

  • To review the efficacy of cyclophosphamide in neurologic lupus.
  • To examine the use of cyclophosphamide in multiple sclerosis.
  • To address uncertainties in treating neurologic autoimmune conditions.

Main Methods:

  • Literature review of clinical trials and studies.
  • Analysis of cyclophosphamide's role in autoimmune neurologic diseases.
  • Focus on lupus nephritis, vasculitis, Wegener's, and multiple sclerosis.

Related Experiment Videos

Main Results:

  • Cyclophosphamide is effective for lupus nephritis.
  • Evidence for efficacy in severe vasculitis and Wegener's is lacking.
  • Limited data exists for cyclophosphamide in neurologic conditions due to diagnostic and monitoring challenges.

Conclusions:

  • Cyclophosphamide remains a key therapy for lupus nephritis.
  • Further research is needed to clarify cyclophosphamide's role in neurologic autoimmune diseases.
  • Objective measures are crucial for evaluating treatment response in neurologic conditions.